hello@apconix.com

Alleviating the Long-term Cardiotoxicity of Cancer Therapies

Alleviating the Long-term Cardiotoxicity of Cancer Therapies Kimberly Rockley completed her PhD in the Division of Pharmacy at Durham University before joining us at ApconiX in June last year. Her research utilised in vitro cardiomyocyte models to investigate the link between angiotensin signalling and anthracycline-induced cardiotoxicity. Here she describes [...]

By |2021-08-12T15:39:04+01:00January 16th, 2020|Toxicology|Comments Off on Alleviating the Long-term Cardiotoxicity of Cancer Therapies
Read More

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in patients with advanced solid tumors.

Phase I dose-escalation study of AZD7762 Abstract: Purpose AZD7762 is a Chk1 kinase inhibitor which increases sensitivity to DNA-damaging agents, including gemcitabine. We evaluated the safety of AZD7762 monotherapy and with gemcitabine in advanced solid tumor patients. Experimental design In this Phase I study, patients received intravenous AZD7762 on [...]

By |2023-01-18T14:38:37+00:00March 20th, 2014|Publications, Toxicology|Comments Off on Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in patients with advanced solid tumors.
Read More
Copyright ApconiX | All Rights Reserved | Website by Greenlight Web
Go to Top